|[August 12, 2014]
Boehringer Ingelheim Vetmedica Acquires Licensing Rights for Artilysin® Technology from Lysando AG
REGENSBURG, Germany --(Business Wire)--
Artilysin®, a new and innovative
technological approach in the fight against pathogenic and
multi-resistant bacteria, developed by the research & development
company Lysando, has arrived in the pharmaceutical industry. Boehringer
Ingelheim Vetmedica has secured the licensing rights for the technology
platform Artilysin®. The company is hopeful to receive significant
momentum and solutions from this new substance class for the problem of
multi-resistant bacteria, which also is an increasing threat to the
Artilysin®s are proteins that, through a physical mechanism,
selectively eliminate pathogenic, multi-resistant and persisting
bacteria. By way of license, Boehringer Ingelheim Vetmedica is taking
advantage of the possibilities presented by this technology. The scope
of applications for Artilysin®s spans from human and animal
medicine to the food industry and the area of hygiene. Theywork quickly
and with their "friend or foe" identification very specifically and are
completely biodegradable. Additionally, no resistances occurred during
the expansive studies. Multi-resistant bacteria pose a significant
threat to health due to the increasing ineffectiveness of antibiotics.
The EU Commission estimates the annual number of deaths caused by
multi-resistant bacteria at 25,000. Massive economic effects are linked
to this fact.
The Boehringer Ingelheim Group is among the 20 leading pharmaceutical
companies worldwide. Their focus areas include research & development,
production and marketing of new medicines with significant therapeutic
benefits for human and animal health. In 2013, Boehringer Ingelheim
reported revenues of appr. 14.1 bn Euros.
Lysando itself is not a manufacturer of pharmaceutical products nor will
it become one in the future; it only provides its new technology
platform through licensing. „The acquisition of licensing rights for the
Artilysin® technology by Boehringer Ingelheim Vetmedica is a
decisive step in the acceptance of this new class of substances",
explains Markus Matuschka v. Greiffenclau, CEO of Lysando AG.
Lysando AG is a technology leader in the area of antimicrobial proteins.
Since its foundation in 2009, the privately financed research company
has done research on artificial designer proteins with a team of
scientists in the town of Regensburg. Artilysin®s represent a
revolutionary breakthrough in the battle against multi-resistant
bacteria. With this new technology platform, drugs and substances
against pathogenic gram-negative and gram-positive bacteria can be
specifically developed, both for antibiotic-resistant and persisting
bacteria. With Artilysin®s, Lysando has created an effective
alternative to antibiotics.
[ Back To TMCnet.com's Homepage ]